Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers

European Journal of Clinical Pharmacology

Volumn 67, Issue 1, 2011, Pages 25-31

  Wang, Yongqing ^a   Yuan, Yaozong ^b   Meng, Ling ^a   Fan, Hongwei ^a   Xu, Jianming ^c   Zhang, Hongwen ^a   Wang, Meifeng ^a   Yuan, Hongyu ^a   Ou, Ning ^a   Zhang, Haibo ^a   Chao, Yang ^d   Shi, Ruihua ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c ANHUI MEDICAL UNIVERSITY   (China)

^d Nanjing chang'Ao Pharmaceutical Science and Technology Co Ltd   (China)

Author keywords

Cytochrome P450 2C19 genotype; Intragastric pH; Pharmacokinetics; Proton pump inhibitors (PPIs); Rabeprazole

Indexed keywords

CYTOCHROME P450 2C19; RABEPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MULTICENTER STUDY; NORMAL HUMAN; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTRIC ACIDITY DETERMINATION; GENOTYPE; HUMANS; HYDROGEN-ION CONCENTRATION; INJECTIONS, INTRAVENOUS; MALE; YOUNG ADULT;

EID: 79151476998     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0949-4     Document Type: Article

References (24)

1. M Robinson 2004 Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors-overview and clinical implications Aliment Pharmacol Ther 20 S1 S10 10.1111/j.1365-2036.2004.02160.x
2. P Miner Jr PO Katz Y Chen M Sostek 2003 Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study Am J Gastroenterol 98 2616 2620 1:CAS:528: DC%2BD3sXpvVahs7o%3D 10.1111/j.1572-0241.2003.08783.x 14687806
3. D Pantoflickova G Dorta M Ravic P Jornod AL Blum 2003 Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors Aliment Pharmacol Ther 17 1507 1514 1:CAS:528:DC%2BD3sXmt1Ogur8%3D 10.1046/j.1365-2036. 2003.01496.x 12823153
4. M Besancon A Simon G Sachs JM Shin 1997 Sites of reaction of the gastric H, K-ATPase with extracytoplasmic thiol reagents J Biol Chem 272 22438 22446 1:CAS:528:DyaK2sXlvFGitr4%3D 10.1074/jbc.272.36.22438 9278394
5. M Miura S Satoh H Tada T Habuchi T Suzuki 2006 Stereoselective metabolism of rabeprazole-thioether to rabeprazole by human liver microsomes Eur J Clin Pharmacol 62 113 117 1:CAS:528:DC%2BD28XivFSgsrw%3D 10.1007/s00228-005-0077-8 16389533
6. S Shi U Klotz 2008 Proton pump inhibitors: an update of their clinical use and pharmacokinetics Eur J Clin Pharmacol 64 935 951 1:CAS:528: DC%2BD1cXht1Sqs7jN 10.1007/s00228-008-0538-y 18679668
7. K Ariizumi S Ohara T Koike Y Inomata K Iijima H Sekine M Noguchi K Sugiyama Y Eda S Kayaba M Kawamura T Shimosegawa 2006 Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism J Gastroenterol Hepatol 21 1428 1434 1:CAS:528:DC%2BD28XhtVOqtLnF 16911688
8. M Kawamura S Ohara T Koike K Iijima J Suzuki S Kayaba K Noguchi S Hamada M Noguchi T Shimosegawa 2003 The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism Aliment Pharmacol Ther 17 965 973 1:CAS:528:DC%2BD3sXjslSrsb4%3D 10.1046/j.1365-2036.2003.01539.x 12656699
9. K Sugano 2002 Rabeprazole: quest for the best PPI J Gastroenterol 37 233 234 10.1007/s005350200028 11931540
10. S Warrington K Baisley M Boyce B Tejura A Morocutti N Miller 2002 Effects of rabeprazole, 20 mg, and esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects Aliment Pharmacol Ther 16 1301 1307 1:CAS:528:DC%2BD38XntVCjsrg%3D 10.1046/j.1365-2036.2002.01292.x 12144580
11. HO Yamano HO Matsushita S Yanagiwara 2008 Plasma concentration of rabeprazole after 8-week administration in gastroesophageal reflux disease patients and intragastric pH elevation J Gastroenterol Hepatol 23 534 540 1:CAS:528:DC%2BD1cXmsV2nsLw%3D 10.1111/j.1440-1746.2007.05104.x 17725594
12. M Robinson S Fitzgerald R Hegedus A Murthy L Jokubaitis 2002 Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis Aliment Pharmacol Ther 16 445 454 1:CAS:528:DC%2BD38XivV2ltLY%3D 10.1046/j.1365-2036.2002.01181.x 11876697
13. A Caos J Breiter C Perdomo J Barth 2005 Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States Aliment Pharmacol Ther 22 193 202 1:CAS:528:DC%2BD2MXhtVagsrfF 10.1111/j.1365-2036.2005. 02555.x 16091056
14. P Miner Jr W Orr J Filippone L Jokubaitis S Sloan 2002 Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial Am J Gastroenterol 97 1332 1339 1:CAS:528:DC%2BD2MXjtFGnsLs%3D 10.1111/j.1572-0241.2002.05769.x 12094846
15. AH Soll R Fass 2003 Gastroesophageal reflux disease: presentation and assessment of a common, challenging disorder Clin Cornerstone 5 2 14 10.1016/S1098-3597(03)90095-0 15101491
16. YQ Wang HW Zhang L Meng MF Wang HY Yuan N Ou HB Zhang ZY Li RH Shi 2010 Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administrated by intravenously successive infusion in Chinese healthy volunteers Eur J Clin Pharmacol 66 563 569 1:CAS:528:DC%2BC3cXmtFWqt7k%3D 10.1007/s00228-010-0821-6 20414645
17. T Ando T Ishikawa S Kokura Y Naito N Yoshida T Yoshikawa 2008 Endoscopic analysis of gastric ulcer after one week's treatment with omeprazole and rabeprazole in relation to CYP2C19 genotype Dig Dis Sci 53 933 937 1:CAS:528:DC%2BD1cXjt1Wit7g%3D 10.1007/s10620-007-9965-3 17934830
18. T Sakai N Aoyama T Kita T Sakaeda K Nishiguchi Y Nishitora T Hohda D Sirasaka T Tamura Y Tanigawara M Kasuga K Okumura 2001 CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects Pharm Res 18 721 727 1:CAS:528:DC%2BD3MXlt1CqtLg%3D 10.1023/A:1011035007591 11474773
19. DR Sohn JT Kwon HK Kim T Ishizaki 1997 Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status Clin Pharmacol Ther 61 574 582 1:CAS:528:DyaK2sXjvVamsr0%3D 10.1016/S0009- 9236(97)90137-5 9164419
20. YM Hu JM Xu Q Mei XH Xu SY Xu 2005 Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects Acta Pharmacol Sin 26 384 388 1:CAS:528:DC%2BD2MXisFGitrk%3D 10.1111/j.1745-7254.2005.00047.x 15715938
21. SC Sim C Risinger ML Dahl E Aklillu M Christensen L Bertilsson M Ingelman-Sundberg 2006 A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants Clin Pharmacol Ther 79 103 113 1:CAS:528:DC%2BD28XksVGltw%3D%3D 10.1016/j.clpt.2005.10.002 16413245
22. RM Baldwin S Ohlsson RS Pedersen J Mwinyi M Ingelman-Sundberg E Eliasson L Bertilsson 2008 Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers Br J Clin Pharmacol 65 767 774 1:CAS:528:DC%2BD1cXmsV2hsrw%3D 10.1111/j.1365-2125.2008. 03104.x 18294333
23. S Sachs JM Shin O Vagin N Lambrecht I Yakubov K Munson 2007 The gastric H,K ATPase as a drug target: past, present, and future J Clin Gastroenterol 41 S226 S242 1:CAS:528:DC%2BD2sXmsFKjtr4%3D 10.1097/MCG.0b013e31803233b7 17575528
24. Sachs G (2001) Improving on PPI-based therapy of GORD. Eur J Gastroenterol Hepatol 13:S35-S41.